SUBSCRIBE: Apple Podcasts | Spotify
In this episode, Dr. Morgentaler and Dr. Brandon discuss the controversial topic of testosterone therapy for men diagnosed with or treated for prostate cancer.
- 00:00 – Introduction to Testosterone and Prostate Cancer: Dr. Morgentaler and Dr. Brandon set the stage by addressing common concerns about testosterone therapy for men with prostate cancer.
- 01:15 – Impact of Androgen Deprivation Therapy: They discuss the effects of lowering testosterone on patients undergoing prostate cancer treatment and the long-term implications on quality of life.
- 03:22 – Debunking Myths About Testosterone: The hosts confront the persistent fears surrounding testosterone and its perceived link to cancer recurrence.
- 07:40 – Scientific Evidence and Case Studies: Highlighting studies and patient stories, they provide evidence that challenges outdated beliefs about testosterone therapy.
- 20:04 – The Impact of Metastatic Disease on Life: They explore how metastatic prostate cancer affects physical and emotional well-being, emphasizing the need for balanced treatment approaches.
- 21:28 – Understanding Biochemical Recurrence: The podcast explains the concept of biochemical recurrence, where cancer returns without visible signs, and its implications for therapy.
- 23:37 – Testosterone Therapy After Prostate Cancer: They detail when and how testosterone therapy might be appropriate for patients post-treatment, backed by promising research data.
- 36:00 – Concluding Thoughts and Future Directions: Wrapping up, they advocate for rethinking testosterone therapy guidelines and encourage further research to support evidence-based care.
Resources
- Watson, E., Chowdhury, S., & Williams, S. G. (2023). Testosterone therapy and prostate cancer: An update on current evidence and practice. Current Opinion in Urology, 33(6), 387–394. https://doi.org/10.1097/MOU.0000000000000989
- Fralick, M., Kim, S. C., Schneeweiss, S., Glynn, R. J., Mittleman, M. A., Lee, H., & Patorno, E. (2023). Testosterone replacement therapy and risk of major adverse cardiovascular events. The New England Journal of Medicine, 388(10), 867–877. https://doi.org/10.1056/NEJMoa2215025
